Seaport Therapeutics IPO: offering terms from its S-1
Seaport Therapeutics priced its IPO at $18 a share on 1 May 2026 and raised $255 million. Its shares trade on Nasdaq as SPTX.
Headlines
- Net loss, 2025
- $75M
- IPO price
- $18
- $255M raised
Seaport Therapeutics IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- SPTX
- IPO price
- $18
- Shares offered
- 14,160,000
- Raised
- $255M
- Registered
- $244M, the amount the filing fee is paid on
- Underwriters
- Goldman Sachs & Co. LLC, J.P. Morgan, Leerink Partners, Citigroup and Stifel
- First filed
- 10 Apr 2026
Seaport Therapeutics revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2025 | - | -$87M | -$75M |
Seaport Therapeutics share structure and company facts
- Share classes and votes
- Voting common stock: 1 vote per share, Non-voting common stock: 0 votes per share
- Employees
- 58
- Headquarters
- Boston, Massachusetts
Seaport Therapeutics shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $18
- Priced 1 May 2026
- First close
- $19.84
- +10% on the IPO price
- Latest close
- $20.83
- +16% on the IPO price
Seaport Therapeutics' IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Seaport Therapeutics' newest prospectus (424B4 filed 1 May 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.